This study focuses on patients with membranous nephropathy, a kidney condition that causes protein loss in urine and low protein levels in blood. The study will test two different approaches for giving the medication rituximab, which is administered through intravenous infusion (given directly into a vein).

The purpose of this research is to compare two methods of giving rituximab treatment: a standard approach versus a personalized approach that uses artificial intelligence to determine the most appropriate dose for each patient. The personalized approach uses a computer algorithm to predict whether a patient might receive too little of the medication after three months of treatment.

During the study, patients will receive rituximab infusions over a period of 45 days. The maximum daily dose is 1 gram, with a total maximum dose of 4 grams during the treatment period. Patients will be monitored for changes in their kidney function and protein levels in their blood and urine. The study will track how well the treatment works for up to 12 months after the first dose of rituximab.